2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial

2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial

Abstract Background At present, no single efficacious therapeutic exists for acute COVID-19 management and a multimodal approach may be necessary. 2-deoxy-d-glucose (2-DG) is a metabolic inhibitor that has been shown to limit multiplication of SARS-CoV-2 in-vitro. We evaluated the efficacy and safet...

Full description

Bibliographic Details
Main Authors: Anant Narayan Bhatt, Srinivas Shenoy, Sagar Munjal, Vijayakumar Chinnadurai, Apurva Agarwal, A. Vinoth Kumar, A. Shanavas, Ratnesh Kanwar, Sudhir Chandna
Format: Article
Language:English
Published: BMC 2022-08-01
Series:BMC Infectious Diseases
Subjects:
COVID-19
SARS-CoV-2
2-deoxy-d-glucose
Randomised clinical trial
Online Access:https://doi.org/10.1186/s12879-022-07642-6

Internet

https://doi.org/10.1186/s12879-022-07642-6

Similar Items